PURPOSE: To analyze the relationship between pre-treatment measurements of tumor oxygen tension (pO2) and survival in advanced head and neck cancer. PATIENTS AND METHODS: Eppendorf pO2 measurements in 397 patients from seven centers were analyzed using the fraction of pO2 values < or =2.5 mmHg (HP2.5), < or =5 mmHg (HP5) and median tumor pO2 (mmHg) as descriptors. All patients had intended curative radiation therapy alone or as pre- or post-operative radiotherapy or radio-chemotherapy according to the practice at each center. RESULTS: The degree of hypoxia varied between tumors with an overall median tumor pO2=9 mmHg (range 0-62 mmHg), a median HP2.5=19% (range 0-97%) and HP5=38%, (range 0-100%). By quadratic regression median tumor pO2 correlated with Hb (2P=0.026, n=357), while HP2.5 or HP5 did not. HP2.5 above the population median was the only parameter that associated with poor overall survival (Kaplan Meier analysis, P=0.006). In a multivariate Cox Proportional Hazards analysis, stratified according to institution HP2.5 was by far the most statistically significant factor in explaining the variability in survival. After adjusting for HP2.5, clinical stage, radiation dose and surgery hemoglobin concentration was not significant in the model. The prognostic model shows that the 5-year survival is almost constant for HP2.5 values in the range from 0 to 20%, whereas the 5-year survival approaches 0% in the most hypoxic tumors. CONCLUSION: This study provides evidence that tumor hypoxia is associated with a poor prognosis in patients with advanced head and neck cancer.
PURPOSE: To analyze the relationship between pre-treatment measurements of tumor oxygen tension (pO2) and survival in advanced head and neck cancer. PATIENTS AND METHODS: Eppendorf pO2 measurements in 397 patients from seven centers were analyzed using the fraction of pO2 values < or =2.5 mmHg (HP2.5), < or =5 mmHg (HP5) and median tumor pO2 (mmHg) as descriptors. All patients had intended curative radiation therapy alone or as pre- or post-operative radiotherapy or radio-chemotherapy according to the practice at each center. RESULTS: The degree of hypoxia varied between tumors with an overall median tumor pO2=9 mmHg (range 0-62 mmHg), a median HP2.5=19% (range 0-97%) and HP5=38%, (range 0-100%). By quadratic regression median tumor pO2 correlated with Hb (2P=0.026, n=357), while HP2.5 or HP5 did not. HP2.5 above the population median was the only parameter that associated with poor overall survival (Kaplan Meier analysis, P=0.006). In a multivariate Cox Proportional Hazards analysis, stratified according to institution HP2.5 was by far the most statistically significant factor in explaining the variability in survival. After adjusting for HP2.5, clinical stage, radiation dose and surgery hemoglobin concentration was not significant in the model. The prognostic model shows that the 5-year survival is almost constant for HP2.5 values in the range from 0 to 20%, whereas the 5-year survival approaches 0% in the most hypoxic tumors. CONCLUSION: This study provides evidence that tumor hypoxia is associated with a poor prognosis in patients with advanced head and neck cancer.
Authors: Lauren Averett Byers; F Christopher Holsinger; Merrill S Kies; William N William; Adel K El-Naggar; J Jack Lee; Jianhua Hu; Adriana Lopez; Hai T Tran; Shaoyu Yan; Zhiqiang Du; K Kian Ang; Bonnie S Glisson; Maria Gabriela Raso; Ignacio I Wistuba; Jeffrey N Myers; Waun-Ki Hong; Vali Papadimitrakopoulou; Scott M Lippman; John V Heymach Journal: Mol Cancer Ther Date: 2010-06-08 Impact factor: 6.261
Authors: Vlad C Sandulache; Yunyun Chen; Heath D Skinner; Tongtong Lu; Lei Feng; Laurence E Court; Jeffrey N Myers; Raymond E Meyn; Clifton D Fuller; James A Bankson; Stephen Y Lai Journal: Mol Cancer Ther Date: 2015-09-16 Impact factor: 6.261
Authors: David J Carlson; Paul J Keall; Billy W Loo; Zhe J Chen; J Martin Brown Journal: Int J Radiat Oncol Biol Phys Date: 2010-12-22 Impact factor: 7.038
Authors: John D Martin; Dai Fukumura; Dan G Duda; Yves Boucher; Rakesh K Jain Journal: Cold Spring Harb Perspect Med Date: 2016-12-01 Impact factor: 6.915
Authors: B Clavo; F Robaina; D Fiuza; A Ruiz; M Lloret; D Rey-Baltar; P Llontop; A Riveros; J Rivero; F Castañeda; S Quintero; N Santana-Rodríguez Journal: Clin Transl Oncol Date: 2016-08-15 Impact factor: 3.405
Authors: Jacobus F A Jansen; Heiko Schöder; Nancy Y Lee; Ya Wang; David G Pfister; Matthew G Fury; Hilda E Stambuk; John L Humm; Jason A Koutcher; Amita Shukla-Dave Journal: Int J Radiat Oncol Biol Phys Date: 2009-11-10 Impact factor: 7.038